Feature

Casp-Aid targeting neuronal neurodegeneration to restore cognition in Alzheimer disease

Closely held Casp-Aid is advancing a differentiated therapeutic strategy aimed at repairing damaged neurons responsible for cognitive impairment by targeting the root cause of neuronal damage in Alzheimer disease (AD)...

March 3, 2026

Feature

MediWound healing without surgery through a pineapple-derived enzymatic approach

MediWound (NASDAQ: MDWD) is advancing a proprietary enzymatic platform derived from bromelain, a proteolytic enzyme extracted from pineapple stems. The company’s non-surgical approach to necrotic tissue removal has...

February 24, 2026

Feature

Imviva closing the gap between autologous and off-the-shelf CAR-T

Closely held Imviva Biotech is advancing a next-generation approach to cell therapy designed to overcome some of the most persistent barriers facing allogeneic CAR-T development. By combining proprietary gene editing...

February 17, 2026

Feature

Astrocyte delivering first-in-class approach to brain injury neuroprotection

Closely held Astrocyte Pharmaceuticals is developing a new category of neuroprotective therapies aimed at reducing early brain damage following stroke, concussion, and traumatic brain injury (TBI). By harnessing the...

February 3, 2026